1. Home
  2. PRAX vs GRDN Comparison

PRAX vs GRDN Comparison

Compare PRAX & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • GRDN
  • Stock Information
  • Founded
  • PRAX 2015
  • GRDN 2004
  • Country
  • PRAX United States
  • GRDN United States
  • Employees
  • PRAX N/A
  • GRDN N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • GRDN Retail-Drug Stores and Proprietary Stores
  • Sector
  • PRAX Health Care
  • GRDN Consumer Staples
  • Exchange
  • PRAX Nasdaq
  • GRDN Nasdaq
  • Market Cap
  • PRAX 1.2B
  • GRDN 1.1B
  • IPO Year
  • PRAX 2020
  • GRDN 2024
  • Fundamental
  • Price
  • PRAX $74.92
  • GRDN $17.14
  • Analyst Decision
  • PRAX Strong Buy
  • GRDN
  • Analyst Count
  • PRAX 9
  • GRDN 0
  • Target Price
  • PRAX $144.11
  • GRDN N/A
  • AVG Volume (30 Days)
  • PRAX 295.5K
  • GRDN 348.2K
  • Earning Date
  • PRAX 11-05-2024
  • GRDN 11-15-2024
  • Dividend Yield
  • PRAX N/A
  • GRDN N/A
  • EPS Growth
  • PRAX N/A
  • GRDN N/A
  • EPS
  • PRAX N/A
  • GRDN N/A
  • Revenue
  • PRAX $1,771,000.00
  • GRDN $1,119,255,000.00
  • Revenue This Year
  • PRAX N/A
  • GRDN N/A
  • Revenue Next Year
  • PRAX N/A
  • GRDN N/A
  • P/E Ratio
  • PRAX N/A
  • GRDN $80.32
  • Revenue Growth
  • PRAX 20.97
  • GRDN 14.66
  • 52 Week Low
  • PRAX $13.01
  • GRDN $14.16
  • 52 Week High
  • PRAX $75.73
  • GRDN $20.10
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 71.35
  • GRDN N/A
  • Support Level
  • PRAX $60.73
  • GRDN N/A
  • Resistance Level
  • PRAX $65.87
  • GRDN N/A
  • Average True Range (ATR)
  • PRAX 3.85
  • GRDN 0.00
  • MACD
  • PRAX 1.22
  • GRDN 0.00
  • Stochastic Oscillator
  • PRAX 96.03
  • GRDN 0.00

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Share on Social Networks: